Volume 19, Issue 7, Pages (July 2011)

Slides:



Advertisements
Similar presentations
Targeting Improves MSC Treatment of Inflammatory Bowel Disease
Advertisements

Fig. 1. TLR4 expression is much greater on macrophages than on DCs
Molecular Therapy - Oncolytics
Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?
Volume 42, Issue 2, Pages (February 2015)
Volume 34, Issue 3, Pages (March 2011)
Volume 42, Issue 3, Pages (March 2015)
Volume 139, Issue 3, Pages (September 2010)
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
Volume 141, Issue 1, Pages e1 (July 2011)
Volume 136, Issue 4, Pages e3 (April 2009)
Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer by Ou Cao, Eric Dobrzynski,
Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine  Weiqing Jing,
Volume 15, Issue 2, Pages (February 2007)
by Norman Nausch, Ioanna E
Volume 17, Issue 8, Pages (August 2009)
Volume 22, Issue 1, Pages (January 2014)
Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic.
IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs  Chien-Chang Chen, PhD, Takao Kobayashi, PhD, Koji Iijima,
Volume 13, Issue 6, Pages (November 2015)
Molecular Therapy - Oncolytics
Targeting Improves MSC Treatment of Inflammatory Bowel Disease
Volume 42, Issue 5, Pages (May 2015)
Volume 19, Issue 8, Pages (August 2011)
Volume 22, Issue 12, Pages (December 2014)
Volume 18, Issue 5, Pages (May 2003)
Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses  William H.D. Hallett, Erik Ames, Maite.
Volume 28, Issue 1, Pages (January 2008)
Volume 140, Issue 7, Pages (June 2011)
Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors by Amine Meliani, Florence Boisgerault, Zachary.
Volume 138, Issue 2, Pages (February 2010)
Volume 29, Issue 1, Pages (July 2008)
Volume 26, Issue 1, Pages (January 2018)
Volume 18, Issue 2, Pages (February 2010)
In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.
Transforming Growth Factor-β Signaling Controls the Formation and Maintenance of Gut-Resident Memory T Cells by Regulating Migration and Retention  Nu.
Molecular Therapy - Methods & Clinical Development
Volume 26, Issue 1, Pages (January 2018)
Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen- Specific Regulatory T Cells  Dan Blat, Ehud Zigmond, Zoya Alteber,
Volume 13, Issue 2, Pages (October 2015)
Volume 29, Issue 6, Pages (December 2008)
Volume 27, Issue 3, Pages (September 2007)
Molecular Therapy - Oncolytics
Volume 36, Issue 6, Pages (June 2012)
Hannah Chen, Padma Sampath, Weizhou Hou, Stephen H. Thorne 
Volume 34, Issue 3, Pages (March 2011)
Volume 42, Issue 1, Pages (January 2015)
Volume 29, Issue 1, Pages (July 2008)
Volume 17, Issue 2, Pages (February 2009)
Volume 29, Issue 1, Pages (July 2008)
Volume 46, Issue 4, Pages (April 2017)
Volume 24, Issue 1, Pages (January 2016)
Molecular Therapy - Oncolytics
In Vivo Expansion of Regulatory T cells With IL-2/IL-2 mAb Complexes Prevents Anti- factor VIII Immune Responses in Hemophilia A Mice Treated With Factor.
Volume 21, Issue 1, Pages (January 2017)
Volume 28, Issue 5, Pages (May 2008)
Volume 18, Issue 12, Pages (December 2010)
Volume 18, Issue 6, Pages (June 2010)
Moutih Rafei, Elena Birman, Kathy Forner, Jacques Galipeau 
Volume 25, Issue 4, Pages (April 2017)
Volume 25, Issue 12, Pages e5 (December 2018)
Volume 24, Issue 1, Pages (January 2016)
Volume 30, Issue 2, Pages (February 2009)
Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After Administration  Yan Li, John Fung, Feng Lin  Molecular Therapy 
Loss of Transgene following ex vivo Gene Transfer is Associated with a Dominant Th2 Response: Implications for Cutaneous Gene Therapy  Zhenmei Lu, Soosan.
Volume 20, Issue 6, Pages (June 2012)
Volume 23, Issue 6, Pages (June 2015)
Volume 13, Issue 11, Pages (December 2015)
Volume 45, Issue 5, Pages (November 2016)
Volume 2, Issue 6, Pages (December 2012)
Presentation transcript:

Volume 19, Issue 7, Pages 1263-1272 (July 2011) Nonredundant Roles of IL-10 and TGF-β in Suppression of Immune Responses to Hepatic AAV-Factor IX Gene Transfer  Brad E Hoffman, Ashley T Martino, Brandon K Sack, Ou Cao, Gongxian Liao, Cox Terhorst, Roland W Herzog  Molecular Therapy  Volume 19, Issue 7, Pages 1263-1272 (July 2011) DOI: 10.1038/mt.2011.33 Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Interleukin-10 (IL-10) deficient C57BL/6 mice fail to form antibodies to hF.IX and remain tolerant after challenge with antigen. (a–b) IL-10 deficient C57BL/6 (n = 4) received hepatic gene transfer with 1011 vector genomes of AAV2-ApoE/hAAT-hF.IX via injection into the splenic capsule. They subsequently received s.c challenge 6 weeks later with 5 µg rhF.IX emulsified in CFA. (a) Plasma levels of hF.IX measured by enzyme-linked immunosorbent assay and (b) immunoglobulin (Ig) G1 anti-hF.IX measured by immuno-capture assay as a function of time after. (c) Control C57BL/6WT and C57BL/6IL10− mice (n = 3 per group) were immunized with 5 µg rhF.IX/CFA. Anti-hF.IX IgG1 was determined beginning 2 weeks later. All data are mean ± SEM. Molecular Therapy 2011 19, 1263-1272DOI: (10.1038/mt.2011.33) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Adoptively transferred regulatory T-cells from tolerized C57BL/6WT and C57BL/6IL10− mice equally suppress antibody formation against hF.IX. (a) CD4+CD25+ T-cells were isolated and pooled from the spleens of C57BL/6WT and C57BL/6IL10− that were either naive or immunized with 1011 vector genomes of AAV2-ApoE/hAAT-hF.IX via injection into the splenic capsule (n = 3 per donor group), and adoptively transferred into naive C57BL/6WT via tail vein injection (n = 3 per recipient group). Twenty-four hours later recipient mice were subcutaneously challenged with 5 µg rhF.IX/CFA and (b) immunoglobulin (Ig) G1 titers against hF.IX (mean ± SEM) were determined by immuno-capture assay 2 weeks later. An unpaired two-tailed Student's t-test was used, **P < 0.01. IL, interleukin. Molecular Therapy 2011 19, 1263-1272DOI: (10.1038/mt.2011.33) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 IL-10 deficiency in C3H/HeJ mice results in differential transgene expression following hepatic AAV2-hF.IX gene transfer. (a–d) C3H/HeJIL10− (n = 4) and C3H/HeJWT (n = 4) received hepatic gene transfer with 1011 vector genomes of AAV2-ApoE/hAAT-hF.IX via injection into the splenic capsule. (a) Plasma levels of hF.IX measured by enzyme-linked immunosorbent assay and (b) immunoglobulin (Ig) G1 anti-hF.IX measured by immuno-capture assay were determined 2 and 3 weeks later. Data represent average ± SEM. (c) At 3 weeks, splenocytes isolated from individual AAV2-hF.IX transduced C3H/HeJIL10− and C3H/HeJWT mice were stimulated in vitro with p74 (SGGPHVTEVEGTSFL) or without (mock) and analyzed for INF-γ by ELISpot assay. Staphylococcal enterotoxin B (SEB) was used as a positive control. Data are average values for individual mice (n = 4, with each mouse assayed in quadruplicate). Horizontal bars indicated averages for each group (d). Representative immunofluorescent labeling of liver sections obtained from mice used in a–c at 3 weeks postgene transfer. Lack of hF.IX producing hepatocytes with infiltrating CD8+ T-cells is demonstrated in C3H/HeJIL10− (top panels). In contrast, the C3H/HeJWT (bottom panels) hepatocytes have well organized, characteristic hF.IX expression without CD8+ cells. (e) Amount of hF.IX from total liver protein that was purified from individual wild-type and IL-10 deficient AAV-F.IX transduced C3H/HeJ mice (n = 3 per group). Data are mean ± SEM. F test to compare variances from an unpaired two-tailed Student's t-test was used, ***P < 0.0001. Original magnification: ×100 and ×200. Arrows, CD8+ cells within the parenchyma; arrowhead, CD8+ cell located in a blood vessel. Molecular Therapy 2011 19, 1263-1272DOI: (10.1038/mt.2011.33) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Transforming growth factor-β (TGF-β) blockade reduces systemic hF.IX expression in wild-type C3H/HeJ mice but not C57Bl/6. (a–d) C3H/HeJWT mice (n = 4–7 per group) or (e–f) C57BL/6 (n = 4 per group) received 25 mg/kg α-TGF-β (clone: 11D1) or phosphate-buffered saline (PBS) by intraperitoneal injection prior to hepatic gene transfer and every third day for 2 weeks (gray region in a–b & e–f). Hepatic gene transfer consisted of 1011 vector genomes of AAV2-ApoE/hAAT-hF.IX, administered via injection into the splenic capsule. (a,e) Plasma levels of hF.IX measured by enzyme-linked immunosorbent assay (ELISA) and (b,f) IgG1 anti-hF.IX measured by immuno-capture assay as a function of time after. (c) Amount of hF.IX, as determined by ELISA, from total liver protein that was purified and pooled from 2 different lobes of individual AAV-F.IX transduced C3H/HeJWT mice that received either blocking antibody or PBS (n = 3 per group). Data are mean ±SEM. An unpaired two-tailed Student's t-test was used, *P < 0.05. (d) Representative immunofluorescent labeling of liver sections obtained from mice treated as above at 2.5 weeks postgene transfer. Original magnification: ×100. Molecular Therapy 2011 19, 1263-1272DOI: (10.1038/mt.2011.33) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 TGF-β blockade prevents suppression of effector T-cell responses upon hepatic gene transfer to C3H/HeJ mice. (a–b) C3H/HeJWT mice (n = 3 per group) received 25 mg/kg α-TGF-β (clone: 11D1) or phosphate-buffered saline by intraperitoneal injection prior to hepatic gene transfer and every third day for 2 weeks (gray region in a and b). Hepatic gene transfer consisted of 1011 vector genomes of AAV2-ApoE/hAAT-hF.IX, administered via injection into the splenic capsule. Splenocytes isolated at ∼2.5 weeks were labeled with α-CD3 and α-CD4 and analyzed by flow cytometry. (a) Representative contour plots indicating the percentage of cells pregated for lymphocyte populations based on forward versus side scatter. (b) Combined analysis of the above groups (mean ± SEM). One-way ANOVA with Bonferroni's post-test was used for statistical analysis *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Molecular Therapy 2011 19, 1263-1272DOI: (10.1038/mt.2011.33) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 TGF-β is required to tip the balance of the response toward FoxP3+ regulatory T-cells (Tregs). (a–f) Identification of Treg phenotype by additional immuno-labeling of cells shown in Figure 5. Splenocytes isolated at ∼2.5 weeks were additionally labeled with α-CD3, α-CD4, α-CD25, α-FoxP3 and analyzed by flow cytometry. (a) Representative contour plots of indicating the percentage of cells pregated for lymphocyte populations based on forward versus side scatter. (a) Representative density plots of CD4+ gated populations with percent indicated. (b) Ratio of CD4+FoxP3− (Teff) to CD25hiFoxP3+(Tregs), (c) Ratio of CD3+CD4− (CD8) to CD25hiFoxP3+(Tregs), (d) Percent of CD4+CD25hiFoxP3+(Tregs), (e) Percentage of CD4+FoxP3− (Teff), (f) Percentage of CD4+CD25hiFoxP3− (recently activated Teff). Data are mean ± SEM. One-way ANOVA with Bonferroni's post-test was used for statistical analysis *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Molecular Therapy 2011 19, 1263-1272DOI: (10.1038/mt.2011.33) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 7 α-TGF-β treatment results in a differential expression of Helios in regulatory T-cells (Treg) cells. (a–c) C3H/HeJWT mice (n = 3 per group) received 25 mg/kg α-TGF-β (clone: 11D1) or phosphate-buffered saline by intraperitoneal injection prior to gene transfer and every third day for 2 weeks. Hepatic gene transfer of 1011 vector genomes of AAV2-ApoE/hAAT-hF.IX was administered via injection into the splenic capsule. Intracellular labeling and flow cytometric analysis using α-CD4, α-FoxP3, and α-Helios of splenocytes obtained from individual mice at ∼2.5 weeks postgene transfer. (a) Representative density plots of CD4+ gated populations with percent indicated. (b) Percent CD4+FoxP3+Helios− and (c) CD4+FoxP3+Helios+ cells. (d) Percent of iTregs identified as Helios-Treg (CD4+CD25hiFoxP3+Helios−) and (e) nTregs identified as Helios+ Treg (CD4+CD25hiFoxP3+Helios+). Data are mean ± SEM. An unpaired two-tailed Student's t-test was used, *P < 0.05, **P < 0.01. Molecular Therapy 2011 19, 1263-1272DOI: (10.1038/mt.2011.33) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions